BioSpace News Archive

Portola Pharmaceuticals, Inc.® announced that the Company will participate in the following conferences in March.

Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the addition of Dr. Anne Prener to both the company’s board of directors and scientific advisory board.

Silverback Therapeutics, Inc., a biopharmaceutical company developing a pipeline of systemically delivered, locally active therapies, today announced Peter Thompson, M.D., co-founder, president and chief executive officer, will present corporate updates at the SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020, at 1:45 pm ET at the Lotte New York Palace Hotel

Feb. 24, 2020 13:00 UTC Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG ® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer – ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – – Prescription Drug User Fee Act (PDUFA) Target Action Date Set for June 23, 2020 – CAMBRIDGE, Mass. & OSAKA, Japan--( BUSINESS WIRE )-- Takeda Pharmaceu

Feb. 24, 2020 13:00 UTC GERMANTOWN, Md.--( BUSINESS WIRE )-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for adults with diabetes, presented data that demonstrated real-world use of the Eversense ® CGM System across adult age ranges. Key International Consensus 1 CGM targets were met in many adult patients with

IRVINE, Calif. , Feb. 24, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the Cowen Healthcare Conference at the Boston Marriott Copley Place on Monday, March 2 , 2020. Scott B. Ull

Feb. 24, 2020 13:00 UTC Noveome Biotherapeutics, Inc. to Present at the 8 th Annual Neurodegenerative Drug Development Summit PITTSBURGH--( BUSINESS WIRE )-- Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced that Larry Brown, Sc.D., Executive Vice President and Chief Scientific Officer at Noveome, will prese

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences

Feb. 24, 2020 13:00 UTC Primary Endpoint of Symptom Control Achieved in Phase 2 Dry Eye Disease Formulation Clinical Trial Statistically Significant Combined Data Across Multiple Dry Eye Disease Clinical Trials Suggests Potential Early and Potent Activity in Signs and Symptoms In Head-to-Head Clinical Trial, Tolerability of Reproxalap Superior to that of Xiidra® in Dry Eye Disease Patients over One Hour After Instillation Leading Ocular Surface Disease

On Monday, March 16, 2020 Alpha Dental Excellence will be hosting their 15th annual Emergency Dentistry event.